Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

Abroad (travel likely)RecruitingPHASE2

Conditions

Type 1 Hyperlipoprotenemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Abhimanyu G Garg, MD

    Principal Investigator

    University of Texas Southwestern Medical Center

  • Chandna Vasandani, Ph.D

    Study Director

    University of Texas Southwestern Medical Center